Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) Restructuring Costs (2025)

Silence Therapeutics' Restructuring Costs history spans 1 years, with the latest figure at -$24000.0 for Q4 2025.

  • On a quarterly basis, Restructuring Costs changed N/A to -$24000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a N/A change, with the full-year FY2025 number at $1.3 million, changed N/A from a year prior.
  • Restructuring Costs hit -$24000.0 in Q4 2025 for Silence Therapeutics, down from $1.3 million in the prior quarter.
  • Over the last five years, Restructuring Costs for SLN hit a ceiling of $1.3 million in Q2 2025 and a floor of -$24000.0 in Q4 2025.